Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) Academic Article uri icon

Overview

MeSH Major

  • Endothelin Receptor Antagonists
  • Heart Failure
  • Pyridines
  • Tetrazoles
  • Vasodilator Agents

abstract

  • No currently available agents have been shown in a prospective, randomized, clinical trial to improve outcomes in patients with AHF. Thus, the VERITAS program will provide valuable insights into the effect of tezosentan on clinical outcomes in patients with AHF, as well as hemodynamics and clinical symptoms.

publication date

  • July 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ahj.2005.04.035

PubMed ID

  • 16084150

Additional Document Info

start page

  • 46

end page

  • 53

volume

  • 150

number

  • 1